About harvard biosci - HBIO
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
HBIO At a Glance
Harvard Bioscience, Inc.
84 October Hill Road
Holliston, Massachusetts 01746-1371
| Phone | 1-508-893-8999 | Revenue | 94.14M | |
| Industry | Medical Specialties | Net Income | -12,405,000.00 | |
| Sector | Health Technology | Employees | 355 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
HBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.976 |
| Price to Book Ratio | 1.468 |
| Price to Cash Flow Ratio | 63.80 |
| Enterprise Value to EBITDA | 54.537 |
| Enterprise Value to Sales | 1.405 |
| Total Debt to Enterprise Value | 0.336 |
HBIO Efficiency
| Revenue/Employee | 265,169.014 |
| Income Per Employee | -34,943.662 |
| Receivables Turnover | 6.332 |
| Total Asset Turnover | 0.713 |
HBIO Liquidity
| Current Ratio | 0.821 |
| Quick Ratio | 0.398 |
| Cash Ratio | 0.075 |
HBIO Profitability
| Gross Margin | 52.641 |
| Operating Margin | -4.841 |
| Pretax Margin | -12.392 |
| Net Margin | -13.178 |
| Return on Assets | -9.397 |
| Return on Equity | -18.187 |
| Return on Total Capital | -11.504 |
| Return on Invested Capital | -13.915 |
HBIO Capital Structure
| Total Debt to Total Equity | 70.248 |
| Total Debt to Total Capital | 41.262 |
| Total Debt to Total Assets | 35.134 |
| Long-Term Debt to Equity | 10.074 |
| Long-Term Debt to Total Capital | 5.917 |